[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100531364":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":31,"responsibleParty":46,"collaborators":20,"id":48,"slug":49,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":20,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":57,"enrollmentInfo":58,"targetDuration":20,"studyType":61,"phases":62,"briefSummary":64,"conditions":65,"keywords":20,"overallStatus":34,"whyStopped":20,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"intervention\u002Ftreatment","EXPERIMENTAL","Fludarabine 150mg\u002Fm2 (days -6, -5, -4, -3, -2) Treosulfan 21g\u002Fm2 (days -6, -5, -4) Thymoglobulin (Genzyme) 5mg\u002Fkg (days -5, -4) Rituximab 100mg\u002Fm2 (day -1) Cyclophosphamide 50mg\u002Fkg (days +3, +4)",[13],"Drug: Treosulfan",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Treosulfan","Treosulfan 21mg\u002Fm2 (days -6, -5, -4)",[9],null,[22,27],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Dmitry Balashov, MD, PhD","CONTACT","+74956647091","bala8@yandex.ru",{"name":28,"role":24,"phone":29,"phoneExt":20,"email":30},"Alexandra Laberko, MD, PhD","+74952876570","alexandra.laberko@gmail.com",[32],{"facility":33,"status":34,"city":35,"state":20,"zip":20,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"HSCT department","RECRUITING","Moscow","Russia","RU",{"type":39,"coordinates":40},"Point",[41,42],37.61781,55.75204,{"lat":42,"lon":41},[45],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},{"type":47,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100531364","phase-2-low-dose-treosulfan-based-conditioning-regimen-and-ptcy-in-hsct-for-nijmegen-breakage-syndrome-100531364",false,"NCT06198842","Low Dose Treosulfan Based Conditioning Regimen and PTCy in HSCT for Nijmegen Breakage Syndrome","Clinical Open-label Phase 2 Study of Low Dose Treosulfan Based Conditioning Regimen Efficacy in Hematopoietic Stem Cell Transplantation With Post-transplant Cyclophosphamide for Children Nijmegen Breakage Syndrome","Inclusion Criteria:\n\n1. Patients aged ≥ 3 months and \\\u003C 21 years\n2. Patients diagnosed with NBS eligible for an allogeneic HSCT\n3. Signed written informed consent signed by a parent or legal guardian","ALL","3 Months","21 Years",{"count":59,"type":60},10,"ESTIMATED","INTERVENTIONAL",[63],"PHASE2","The aim of the current study is to evaluate the safety and efficacy of low dose treosulfan based conditioning regimen in HSCT with post-transplant cyclophosphamide in Nijmegen breakage syndrome",[66],"Nijmegen Breakage Syndrome","2023-12-27",{"date":69,"type":70},"2024-01-10","ACTUAL",{"date":72,"type":70},"2023-11-22",{"date":74,"type":60},"2029-01-31",{"name":5,"class":6},1]